Brazil’s CAR T-cell revolution: why a $500,000 cancer cure remains out of reach for most patients

…

The clinical case for expanding access to CAR T-cell therapy in Brazil rests on a substantial body of evidence demonstrating durable responses in patients who have exhausted conventional options. In relapsed or refractory diffuse large B-cell lymphoma, pivotal trials have shown that a meaningful proportion of patients achieve complete remissions that persist for years, a striking contrast to the historically poor prognosis of this population. Similarly, in relapsed or refractory B-cell acute lymphoblastic leukemia, CAR T-cell therapy has produced high remission rates and has become an established bridge or alternative to hematopoietic stem cell transplantation for eligible patients. These outcomes explain why regulatory agencies in the United States, Europe, and Brazil have progressively approved multiple anti-CD19 products, and why the therapy has moved from experimental novelty to standard of care in defined settings. The durability of benefit matters particularly in the Brazilian context, because a single successful infusion can potentially avert years of repeated hospitalizations, transfusions, salvage chemotherapy cycles, and palliative interventions, costs that are often invisible in simple price comparisons between CAR T-cell therapy and conventional treatment pathways.

The manufacturing process underlying these products is central to understanding both their cost and their scarcity. Unlike conventional drugs produced at industrial scale, CAR T-cell therapy is an autologous, patient-specific product. A patient’s T cells are collected through leukapheresis, shipped to a manufacturing facility, genetically engineered to express the chimeric antigen receptor, expanded to therapeutic numbers, subjected to rigorous quality control testing, and then returned to the treatment center for infusion after lymphodepleting chemotherapy. Each step is time-sensitive, since patients with aggressive relapsed disease may progress while their cells are being processed. The logistics chain involves cryopreservation, cold-chain transport, chain-of-identity and chain-of-custody documentation, and specialized laboratory infrastructure operating under good manufacturing practice standards. Every unit is essentially a bespoke biologic, which explains why per-patient manufacturing costs can approach USD 500,000 and why scaling production is fundamentally different from scaling conventional pharmaceutical manufacturing. This structure also creates vulnerability: any disruption at a single manufacturing facility or in the transport chain can delay treatment for patients whose disease will not wait.

The adverse event profile of CAR T-cell therapy further shapes the infrastructure requirements that constrain access. The most recognized toxicities are cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, both of which can range from mild, self-limited episodes to life-threatening emergencies requiring intensive care support. Management depends on grading systems, tocilizumab and corticosteroid protocols, and round-the-clock availability of clinicians experienced in recognizing early signs of deterioration. Treatment centers must also manage prolonged cytopenias, infections, and the rare but serious risk of secondary malignancies that has prompted ongoing long-term safety surveillance. These demands mean that safe delivery requires not only the infusion itself but a comprehensive care ecosystem: apheresis capability, cell processing or reliable transport partnerships, intensive care access, trained nursing staff, and standardized toxicity management protocols. In Brazil, the concentration of such expertise in a limited number of centers in large urban areas means that geography itself becomes a determinant of access, with patients from the North and Northeast regions facing long travel, extended stays away from home, and additional out-of-pocket burdens that compound the direct cost of therapy.

The disparity between Brazil’s Unified Health System and the private insurance market deserves closer examination because it illustrates broader tensions in health systems confronting high-cost cell therapies. The Unified Health System, constitutionally guaranteed to all citizens, operates under fixed budgets and centralized procurement processes that were not designed for therapies with six-figure per-patient costs and complex logistics. Private insurers, meanwhile, face their own pressures from rising claims and contractual disputes over coverage of novel biologics. The result documented by the expert panel is a system in which many patients resort to judicial action to compel coverage, a phenomenon well recognized in Brazilian health policy. Judicialization can deliver treatment to individual patients who possess the resources, legal representation, and health status to pursue litigation, but it does so unevenly and unpredictably, effectively rationing access by capacity to litigate rather than by clinical need. It also imposes costs on the system through legal fees, emergency injunctions, and fragmented procurement that lacks the negotiating leverage of coordinated purchasing. Any sustainable solution must therefore address not only the list price of the products but the structural pathways through which coverage decisions are made and contested.

Domestic manufacturing capacity emerges in the panel’s analysis as a strategic lever with effects beyond cost reduction. Brazil possesses a strong biomedical research base, established cell therapy programs in academic centers, and regulatory institutions capable of overseeing advanced therapies. Building on these assets to produce CAR T-cell products locally could shorten the logistics chain, reduce exposure to currency fluctuations and international supply constraints, and create opportunities for technology transfer agreements that lower unit costs. Local production also enables the development of products adapted to local epidemiology and potentially less expensive constructs, including approaches that reduce manufacturing complexity. However, the panel’s experience suggests that domestic capacity alone is insufficient without parallel progress on reimbursement, since a locally manufactured product still carries substantial production costs and requires a payment mechanism that public and private payers can sustain. The interplay between supply-side investments and demand-side financing is therefore critical: manufacturing initiatives without funding pathways will leave products available but unaffordable, while funding mechanisms without reliable supply will leave budgets committed but patients untreated.

Innovative reimbursement models discussed by the panel merit elaboration because they represent a departure from traditional fee-for-service purchasing. Outcome-based agreements, in which manufacturers receive full or partial payment only when patients achieve defined clinical milestones, align incentives between payers and producers and reduce the financial risk of paying for therapies that may fail in individual patients. Installment or annuity payment structures spread costs over the period during which benefit is realized, easing annual budget impact. Pooled procurement across public institutions or regional consortia can generate volume discounts and standardize treatment protocols. Subscription-style arrangements, in which payers pay a fixed annual amount for access to a defined population, have been explored internationally for other high-cost therapies and could be adapted to cell therapy contexts. Each model carries administrative complexity, requiring robust data systems to track outcomes, contractual frameworks that Brazilian institutions may need to develop, and regulatory clarity about what constitutes acceptable risk-sharing. The panel’s emphasis on these mechanisms reflects a recognition that the binary choice between paying full price and denying treatment is a false one, and that middle paths exist if stakeholders commit to designing them.

Regulatory streamlining represents another dimension of the access challenge with lessons for other jurisdictions. Brazil’s health regulatory agency has already approved several CAR T-cell products, demonstrating that the national framework can evaluate advanced therapy medicinal products. Yet approval is only the first gate; subsequent requirements related to importation, center accreditation, pharmacovigilance reporting, and traceability of cellular products each add time and administrative burden. Harmonizing these processes, clarifying accreditation standards for treatment centers, and establishing clear pathways for domestically manufactured products could compress the interval between regulatory approval and actual patient treatment. The panel’s recommendation to streamline regulatory pathways should be understood not as lowering safety standards but as removing redundant steps and ambiguities that delay access without adding protective value. International experience with regulatory convergence initiatives suggests that alignment with established international standards can accelerate review while maintaining rigor.

The patient advocacy perspective embedded in the panel composition deserves particular attention because it reframes the access debate around lived experience. Patients confronting relapsed or refractory disease face urgent timelines, and every week of administrative delay, insurance negotiation, or litigation carries clinical consequences. Advocacy organizations in Brazil have historically played important roles in expanding access to cancer treatments, and their participation in expert panels signals a shift toward shared decision-making about how cell therapy programs should be designed. Patient-centered considerations include the burden of travel and accommodation during treatment, the psychological toll of prolonged waiting periods, the need for clear information about risks and expected benefits, and support for caregivers who accompany patients through the treatment journey. Incorporating these dimensions into program design, rather than treating them as afterthoughts, improves both the ethical defensibility and the practical functioning of access programs.

The epidemiological context underscores the scale of potential demand. With roughly 23,000 estimated new cases of non-Hodgkin lymphomas and leukemias in Brazil in 2023, and the majority arising from B lymphocytes, the population eligible for anti-CD19 CAR T-cell therapy at some point in their disease course is substantial, even if only a fraction present with relapsed or refractory disease matching current indications. As clinical evidence expands to earlier lines of therapy and additional disease settings, the eligible population will grow, intensifying pressure on supply, infrastructure, and financing. Planning for this trajectory now, rather than reacting to demand crises later, is implicit in the panel’s forward-looking recommendations. Capacity modeling, workforce training pipelines, and phased expansion of accredited centers are the practical instruments through which such planning becomes real.

Finally, the Brazilian experience carries significance well beyond its borders. As the only country in Latin America with current access to CAR T-cell therapy, Brazil functions as a natural experiment in how a large, unequal, federal health system with both strong private markets and universal public commitments can absorb a transformative but costly technology. The panel’s integrated framework, spanning clinical evidence, economics, regulation, infrastructure, and patient perspectives, offers a template that neighboring countries and other resource-limited settings can adapt. The central lesson is that access to advanced therapies is not determined by any single factor but by the alignment of many: manufacturing capacity, regulatory clarity, financing mechanisms, trained personnel, and political commitment to equity. Where these align, innovation reaches patients; where they do not, even approved and clinically proven therapies remain confined to a privileged few. The recommendations emerging from the July 2025 expert panel represent a deliberate attempt to build that alignment, and their implementation over the coming years will be watched closely by health systems worldwide confronting the same fundamental question of how to deliver twenty-first-century medicine within twenty-first-century budgets.

Subject of Research: CAR T-cell therapy access and equity in Brazil

Article Title: Bridging innovation and equity: the evolving landscape of CAR T-cell therapy access in Brazil

Article References: Guerino-Cunha, R. L., Bessa, A., Jansen, A. M., Oliveira, M., Sanku, G., Scarabel, R., Schmidt-Filho, J., & Stefani, S. (2026). Bridging innovation and equity: the evolving landscape of CAR T-cell therapy access in Brazil. Frontiers in Hematology, 5, Article 1813861. https://doi.org/10.3389/frhem.2026.1813861

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1813861

Keywords: CAR T-cell therapy, Brazil, hematologic malignancies, health equity, ANVISA, Unified Health System, immunotherapy, health economics, lymphoma, leukemia, Bridging, innovation